Key Highlights

  • RKDA was down 10.77% to USD 0.1392 in pre-market trading on November 3, 2026.
  • No company announcement dated October 30 to November 3, 2026 was identified as a catalyst.
  • Cash was USD 4.2 million at June 30, 2026, after a USD 4 million private Placement closed in June.
  • Stockholders approved a reverse split between one-for-2 and one-for-10 at the annual meeting reported on September 15, 2026.
  • July 2026 sales of Zola coconut water topped USD 740,000.

What moved the stock in pre-market trading (down USD 0.0168, 10.77%)

Arcadia Biosciences (NASDAQ:RKDA) was down 10.77% to USD 0.1392 in pre-market trading on November 3, 2026, against the November 2, 2026 close. Thin extended-hours trading can exaggerate moves of this size.

A search of company releases and filings dated October 30 to November 3, 2026 found no announcement behind the decline, and the Investor relations page showed no release after August 13, 2026. The move looks like price action in a heavily diluted microcap. Shares under USD 5 are a penny stock, with high volatility, limited Liquidity and dilution risk.

Recent company updates

Arcadia now centers on Zola coconut water, sourced and packaged in Thailand, after selling its GoodWheat Business to another company. A planned combination with Roosevelt Resources ended when the company received a termination notice on December 24, 2025.

On August 13, 2026 it reported second-quarter results: operating cash use of USD 319,000, cash of USD 4.2 million and a closed USD 4 million private placement. It had announced purchase agreements on June 11, 2026 for 3,883,496 shares of common stock, or pre-funded warrants, and the placement closed on June 12, 2026. The first-quarter report on May 14, 2026 cited Zola Volume growth of 18%.

Financial position and risks

The Annual Report filed on March 26, 2026 stated that substantial doubt exists about the ability to continue as a going concern. It showed an accumulated Deficit of USD 281.2 million, year-end 2025 cash of about USD 0.3 million, product Revenue of about USD 4.9 million and a net loss of about USD 2.3 million, compared with USD 7.0 million in 2024.

The same filing noted a proposed Nasdaq minimum Market Value requirement of USD 5 million for listed securities, with delisting possible after 30 consecutive business days below it. It put the company's market value at about USD 3.4 million as of March 19, 2026. The screen price of USD 0.1392 sits far below the roughly USD 1.03 per share calculated from the June placement figures, so the quote should be treated with care.

What to watch next

Stockholders approved a reverse split at a ratio of one-for-2 to one-for-10, exercisable before June 30, 2027, so a split announcement is possible. Investors will also watch the third-quarter report, which was not yet dated in the company's releases, for cash, Zola sales and margins, along with any Nasdaq correspondence.